zolbetuximab
astellas
[]
 presented results from the phase 3 spotlight trial which showed improved pfs of 10.61 mo in the zolbetuximab arm vs 8.67 mo with placebo. #gi23 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.